AI-generated analysis. Always verify with the original filing.
Vivani Medical, Inc. reported fourth quarter and full year 2025 financial results, including a Q4 net loss of $6.6 million and full year net loss of $26.6 million, with cash and equivalents of $16.2 million as of December 31, 2025, supporting operations into mid-2027. The company highlighted successful completion of the LIBERATE-1 first-in-human study and preclinical data for NPM-139 semaglutide implant showing >20% sham-adjusted weight loss for a full year, with Phase 1 study initiation planned for mid-2026.
Event Type
Disclosure
Mandatory
Variant
8-K
and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incor
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release dated March 26, 2026 entitled “ Vivani Medical Reports Fourth Quart